Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

Neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab have been established as the optimal systemic therapies for patients with early stage triple-negative breast cancer (TNBC); however, their efficacy and feasibility in the Japanese population remain unexplored. This study included...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Breast cancer (Tokyo, Japan) Japan), 2024-12
Hauptverfasser:	Aoyama, Yosuke, Ozaki, Yukinori, Kizawa, Rika, Masuda, Jun, Kawai, Saori, Kurata, Mami, Maeda, Tetsuyo, Yoshida, Kazuyo, Yamashita, Nami, Nishimura, Meiko, Hosonaga, Mari, Fukada, Ippei, Hara, Fumikata, Kobayashi, Takayuki, Takano, Toshimi, Ueno, Takayuki
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!